- Advertisement -
A trial of Pfizer’s experimental antiviral pill for COVID-19 has been stopped early after the drug was shown to cut by 89 per cent the chances of hospitalisation or death for adults at risk of severe disease, the company says.
The results appear to surpass those seen with Merck & Co’s pill…
